Yoshinari Orie, Moriyama Hiroyoshi, Shiojima Yoshiaki
a Development Division , Ryusendo Co. Ltd. , Tokyo , JAPAN.
J Am Coll Nutr. 2015;34(3):255-62. doi: 10.1080/07315724.2014.919541. Epub 2015 Mar 9.
Osteoarthritis, the most common form of arthritis, is a crippling, chronic debilitating bone disease that commonly affects humans, dogs, and horses. Inflammation and inflammatory responses are key factors for causing swelling, redness, pain, and loss of movement in arthritic animals and humans.
We developed a novel, water-soluble, undenatured type II collagen (NEXT-II) for osteoarthritis. NEXT-II demonstrated broad-spectrum safety and nonmutagenicity. NEXT-II exhibited significant efficacy in ameliorating pain and inflammation in collagen-induced arthritis in mice. NEXT-II enhanced the proportion of CD4+CD25+T cells, and gene expressions of stimulated dendritic cells induced markers for regulatory T cell such as forkhead box p3, transforming growth factor-β1, and CD25. Furthermore, NEXT-II was assessed in moderately arthritic dogs receiving either placebo or 10 mg NEXT-II over a period of 150 days. NEXT-II exhibited a significant reduction in overall pain, pain after limb manipulation, and pain after physical exertion compared to the control dogs. Physical health and serum chemistry (alanine aminotransferase, blood urea nitrogen, and creatine kinase) were not altered when these arthritic dogs were treated over a period of 150 days.
These results demonstrate the broad-spectrum safety and efficacy of NEXT-II in ameliorating the symptoms of arthritis. Key Teaching Points: •A novel, water-soluble, undenatured type II collagen (NEXT-II) was developed for osteoarthritis. •The safety studies including acute oral and dermal toxicity, primary dermal and primary eye irritation, Ames' bacterial reverse mutation assay, mouse lymphoma assay, and 150-day long-term safety studies were conducted. •NEXT-II exhibited significant efficacy in ameliorating pain and inflammation in collagen-induced arthritis in mice. •NEXT-II exhibited a significant reduction in overall pain in moderately arthritic dogs without changing physical parameters.
骨关节炎是关节炎最常见的形式,是一种致残的慢性衰弱性骨病,通常影响人类、狗和马。炎症和炎症反应是导致关节炎动物和人类肿胀、发红、疼痛和活动受限的关键因素。
我们开发了一种用于骨关节炎的新型水溶性未变性II型胶原蛋白(NEXT-II)。NEXT-II显示出广谱安全性和非致突变性。NEXT-II在改善小鼠胶原诱导性关节炎的疼痛和炎症方面表现出显著疗效。NEXT-II提高了CD4+CD25+T细胞的比例,以及刺激的树突状细胞诱导调节性T细胞标志物(如叉头框p3、转化生长因子-β1和CD25)的基因表达。此外,对中度关节炎犬进行了评估,这些犬在150天内接受安慰剂或10mg NEXT-II治疗。与对照犬相比,NEXT-II在总体疼痛、肢体操作后疼痛和体力消耗后疼痛方面均有显著降低。在对这些关节炎犬进行150天治疗后,其身体健康和血清化学指标(丙氨酸转氨酶、血尿素氮和肌酸激酶)未发生改变。
这些结果证明了NEXT-II在改善关节炎症状方面的广谱安全性和有效性。关键要点:•开发了一种用于骨关节炎的新型水溶性未变性II型胶原蛋白(NEXT-II)。•进行了包括急性口服和皮肤毒性、原发性皮肤和原发性眼刺激、Ames细菌回复突变试验、小鼠淋巴瘤试验以及150天长期安全性研究在内的安全性研究。•NEXT-II在改善小鼠胶原诱导性关节炎的疼痛和炎症方面表现出显著疗效。•NEXT-II在中度关节炎犬中显著降低了总体疼痛,且未改变身体参数。